{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:13:04Z","timestamp":1791267184681,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T00:00:00Z","timestamp":1626652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10384-021-00856-2","type":"journal-article","created":{"date-parts":[[2021,7,19]],"date-time":"2021-07-19T05:02:40Z","timestamp":1626670960000},"page":"598-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of the 24-h efficacy and safety of fixed combination carteolol\/latanoprost and timolol\/latanoprost in patients with primary open-angle glaucoma and ocular hypertension: a prospective crossover study"],"prefix":"10.1007","volume":"65","author":[{"given":"Yuta","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichiro","family":"Kizaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Shibasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuharu","family":"Kishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Aihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"856_CR1","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1016\/S0140-6736(10)61423-7","volume":"377","author":"HA Quigley","year":"2011","unstructured":"Quigley HA. Glaucoma Lancet. 2011;377:1367\u201377.","journal-title":"Glaucoma Lancet"},{"key":"856_CR2","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311:1901\u201311.","journal-title":"JAMA"},{"key":"856_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ophtha.2015.10.053","volume":"123","author":"BE Prum Jr","year":"2016","unstructured":"Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, et al. Primary open-angle glaucoma preferred practice pattern(\u00ae) Guidelines. Ophthalmology. 2016;123:41\u2013111.","journal-title":"Ophthalmology"},{"key":"856_CR4","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s10384-018-0623-4","volume":"63","author":"Y Morizane","year":"2019","unstructured":"Morizane Y, Morimoto N, Fujiwara A, Kawasaki R, Yamashita H, Ogura Y, et al. Incidence and causes of visual impairment in Japan: the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol. 2019;63:26\u201333.","journal-title":"Jpn J Ophthalmol"},{"key":"856_CR5","first-page":"1641","volume":"111","author":"A Iwase","year":"2004","unstructured":"Iwase A, Suzuki Y, Araie M, Yamamoto T, Abe H, Shirato S, et al. The prevalence of primary open-angle glaucoma in Japanese: the Tajimi Study. Ophthalmology. 2004;111:1641\u20138.","journal-title":"Ophthalmology"},{"key":"856_CR6","unstructured":"Gupta D, Chen PP. Glaucoma. Am Fam Physician. 2016;93:668\u201374."},{"key":"856_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10792-018-0820-7","volume":"39","author":"T Tsumura","year":"2019","unstructured":"Tsumura T, Kashiwagi K, Suzuki Y, Yoshikawa K, Suzumura H, Maeda T, et al. A nationwide survey of factors influencing adherence to ocular hypotensive eyedrops in Japan. Int Ophthalmol. 2019;39:375\u201383.","journal-title":"Int Ophthalmol"},{"key":"856_CR8","doi-asserted-by":"publisher","first-page":"7642049","DOI":"10.1155\/2017\/7642049","volume":"2017","author":"M Sakamoto","year":"2017","unstructured":"Sakamoto M, Kitamura K, Kashiwagi K. Changes in glaucoma medication during the past eight years and future directions in Japan based on an Insurance Medical Claim Database. J Ophthalmol. 2017;2017:7642049.","journal-title":"J Ophthalmol"},{"key":"856_CR9","doi-asserted-by":"publisher","first-page":"509","DOI":"10.2165\/00002512-200724060-00007","volume":"24","author":"S Henness","year":"2007","unstructured":"Henness S, Swainston Harrison T, Keating GM. Ocular carteolol: a review of its use in the management of glaucoma and ocular hypertension. Drugs Aging. 2007;24:509\u201328.","journal-title":"Drugs Aging"},{"key":"856_CR10","unstructured":"Tripathy K, Geetha R. Latanoprost. In: StatPearls [Internet]. StatPearls Publishing; 2020. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK540978\/."},{"key":"856_CR11","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/0002-9394(86)90532-5","volume":"102","author":"WL Nelson","year":"1986","unstructured":"Nelson WL, Fraunfelder FT, Sills JM, Arrowsmith JB, Kuritsky JN. Adverse respiratory and cardiovascular events attributed to timolol ophthalmic solution, 1978\u20131985. Am J Ophthalmol. 1986;102:606\u201311.","journal-title":"Am J Ophthalmol"},{"key":"856_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/S0002-9394(14)70172-2","volume":"123","author":"PA Netland","year":"1997","unstructured":"Netland PA, Weiss HS, Stewart WC, Cohen JS, Nussbaum LL. Cardiovascular effects of topical carteolol hydrochloride and timolol maleate in patients with ocular hypertension and primary open-angle glaucoma. Night Study Group Am J Ophthalmol. 1997;123:465\u201377.","journal-title":"Night Study Group Am J Ophthalmol"},{"key":"856_CR13","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S0002-9394(14)70865-7","volume":"124","author":"WC Stewart","year":"1997","unstructured":"Stewart WC, Cohen JS, Netland PA, Weiss H, Nussbaum LL. Efficacy of carteolol hydrochloride 1% vs timolol maleate 0.5 % in patients with increased intraocular pressure; Nocturnal Investigation of Glaucoma Hemodynamics Trial Study Group. Am J Ophthalmol. 1997;124:498\u2013505.","journal-title":"Am J Ophthalmol."},{"key":"856_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1517\/14728214.12.2.313","volume":"12","author":"DF Woodward","year":"2007","unstructured":"Woodward DF, Chen J. Fixed-combination and emerging glaucoma therapies. Expert Opin Emerg Drugs. 2007;12:313\u201327.","journal-title":"Expert Opin Emerg Drugs"},{"key":"856_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1080\/00365510601034736","volume":"67","author":"T Nieminen","year":"2007","unstructured":"Nieminen T, Lehtim\u00e4ki T, M\u00e4enp\u00e4\u00e4 J, Ropo A, Uusitalo H, K\u00e4h\u00f6nen M. Ophthalmic timolol: plasma concentration and systemic cardiopulmonary effects. Scand J Clin Lab Invest. 2007;67:237\u201345.","journal-title":"Scand J Clin Lab Invest"},{"key":"856_CR16","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1034\/j.1600-0420.2001.790604.x","volume":"79","author":"LI Larsson","year":"2001","unstructured":"Larsson LI. Intraocular pressure over 24 hours after single-dose administration of latanoprost 0.005% in healthy volunteers: a randomized, double-masked, placebo controlled, cross-over single center study. Acta Ophthalmol Scand. 2001;79:567\u201371.","journal-title":"Acta Ophthalmol Scand."},{"key":"856_CR17","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/clpt.2009.306","volume":"87","author":"KT Luu","year":"2010","unstructured":"Luu KT, Raber SR, Nickens DJ, Vicini P. A model-based meta-analysis of the effect of latanoprost chronotherapy on the circadian intraocular pressure of patients with glaucoma or ocular hypertension. Clin Pharmacol Ther. 2010;87:421\u20135.","journal-title":"Clin Pharmacol Ther"},{"key":"856_CR18","unstructured":"Ministry of Health, Labour and Welfare. Clinical Trials Act (Act No. 16 of April 14, 2017). https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10800000-Iseikyoku\/0000163413.pdf."},{"key":"856_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.ajo.2016.08.022","volume":"171","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Ikegami T, Ishikawa Y, Kikuchi S. OPC-1085EL 1 & 2 Study Groups. Randomized, controlled, phase 3 trials of carteolol\/latanoprost fixed combination in primary open-angle glaucoma or ocular hypertension. Am J Ophthalmol. 2016;171:35\u201346.","journal-title":"Am J Ophthalmol"},{"key":"856_CR20","first-page":"221","volume":"21","author":"MA Lemp","year":"1995","unstructured":"Lemp MA. Report of the National Eye Institute\/Industry workshop on Clinical Trials in Dry Eyes. CLAO J. 1995;21:221\u201332.","journal-title":"CLAO J"},{"key":"856_CR21","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1080\/14656566.2018.1518432","volume":"19","author":"RR Soares","year":"2018","unstructured":"Soares RR, Razeghinejad MR. Efficacy of the combination of carteolol hydrochloride + latanoprost in the treatment of glaucoma and ocular hypertension. Expert Opin Pharmacother. 2018;19:1731\u20138.","journal-title":"Expert Opin Pharmacother"},{"key":"856_CR22","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1097\/IJG.0000000000001091","volume":"27","author":"K Inoue","year":"2018","unstructured":"Inoue K, Shiokawa M, Iwasa M, Ishida K, Tomita G. Short-term efficacy and safety of a latanoprost\/carteolol fixed combination switched from concomitant therapy to in patients with primary open-angle glaucoma or ocular hypertension. J Glaucoma. 2018;27:1175\u201380.","journal-title":"J Glaucoma"},{"key":"856_CR23","first-page":"2566","volume":"41","author":"N Orzalesi","year":"2000","unstructured":"Orzalesi N, Rossetti L, Invernizzi T, Bottoli A, Autelitano A. Effect of timolol, latanoprost, and dorzolamide on circadian IOP in glaucoma or ocular hypertension. Invest Ophthalmol Vis Sci. 2000;41:2566\u201373.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"856_CR24","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s10384-009-0780-6","volume":"54","author":"K Nakamoto","year":"2010","unstructured":"Nakamoto K, Yasuda N. Effect of carteolol hydrochloride on 24-hour variation of intraocular pressure in normal-tension glaucoma. Jpn J Ophthalmol. 2010;54:140\u20133.","journal-title":"Jpn J Ophthalmol"},{"key":"856_CR25","doi-asserted-by":"crossref","unstructured":"Oddone F, Rossetti L, Tanga L, Berardo F, Ferrazza M, Michelessi M, et al. Effects of topical bimatoprost 0.01% and timolol 0.5% on circadian IOP, blood pressure and perfusion pressure in patients with glaucoma or ocular hypertension: a randomized, double masked, placebo-controlled clinical trial. PLoS One. 2015;10:e0140601.","DOI":"10.1371\/journal.pone.0140601"},{"key":"856_CR26","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/IJG.0b013e31816f760c","volume":"18","author":"JM Martinez-de-la-Casa","year":"2009","unstructured":"Martinez-de-la-Casa JM, Garcia-Feijoo J, Saenz-Frances F, Vizzeri G, Fernandez-Vidal A, Mendez-Hernandez C, et al. Comparison of rebound tonometer and Goldmann handheld applanation tonometer in congenital glaucoma. J Glaucoma. 2009;18:49\u201352.","journal-title":"J Glaucoma"},{"key":"856_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.3928\/01913913-20180621-01","volume":"55","author":"P Arribas-Pardo","year":"2018","unstructured":"Arribas-Pardo P, Mendez-Hern\u00e1ndez C, Valls-Ferran I, Puertas-Bordallo D. Icare-Pro rebound tonometer versus hand-held applanation tonometer for pediatric screening. J Pediatr Ophthalmol Strabismus. 2018;55:382\u20136.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"856_CR28","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3928\/01913913-20191106-01","volume":"57","author":"C Mendez-Hernandez","year":"2020","unstructured":"Mendez-Hernandez C, Arribas-Pardo P, Jean RS, Garcia-Feljoo J. Influence of axial length on intraocular pressure measurement with three tonometers in childhood glaucoma. J Pediatr Ophthalmol Strabismus. 2020;57:27\u201332.","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"856_CR29","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/clc.4960190904","volume":"19","author":"WC Stewart","year":"1996","unstructured":"Stewart WC, Castelli WP. Systemic side effects of topical beta-adrenergic blockers. Clin Cardiol. 1996;19:691\u20137.","journal-title":"Clin Cardiol"},{"key":"856_CR30","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1080\/14740338.2016.1225718","volume":"15","author":"J M\u00e4enp\u00e4\u00e4","year":"2016","unstructured":"M\u00e4enp\u00e4\u00e4 J, Pelkonen O. Cardiac safety of ophthalmic timolol. Expert Opin Drug Saf. 2016;15:1549\u201361.","journal-title":"Expert Opin Drug Saf"},{"key":"856_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/S0002-9394(99)00160-9","volume":"128","author":"SS Hayreh","year":"1999","unstructured":"Hayreh SS, Podhajsky P, Zimmerman MB. Beta-blocker eyedrops and nocturnal arterial hypotension. Am J Ophthalmol. 1999;128:301\u20139.","journal-title":"Am J Ophthalmol"},{"key":"856_CR32","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0161-6420(99)90116-1","volume":"106","author":"C Baudouin","year":"1999","unstructured":"Baudouin C, Pisella PJ, Fillacier K, Goldschild M, Becquet F, De Saint JM, et al. Ocular surface inflammatory changes induced by topical antiglaucoma drugs: human and animal studies. Ophthalmology. 1999;106:556\u201363.","journal-title":"Ophthalmology"},{"key":"856_CR33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.2165\/00002512-199202010-00007","volume":"2","author":"P Chrisp","year":"1992","unstructured":"Chrisp P, Sorkin EM. Ocular carteolol: a review of its pharmacological properties, and therapeutic use in glaucoma and ocular hypertension. Drugs Aging. 1992;2:58\u201377.","journal-title":"Drugs Aging"},{"key":"856_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-4274(01)00261-2","volume":"122","author":"S Burgalassi","year":"2001","unstructured":"Burgalassi S, Chetoni P, Monti D, Saettone MF. Cytotoxicity of potential ocular permeation enhancers evaluated on rabbit and human corneal epithelial cell lines. Toxicol Lett. 2001;122:1\u20138.","journal-title":"Toxicol Lett"},{"key":"856_CR35","first-page":"515","volume":"88","author":"H H\u00f6h","year":"1991","unstructured":"H\u00f6h H, Nastainczyk W. Beta blockers and corneal sensitivity. Article in German Fortschr Ophthalmol. 1991;88:515\u201321.","journal-title":"Article in German Fortschr Ophthalmol"},{"key":"856_CR36","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/00061198-200312000-00007","volume":"12","author":"K Inoue","year":"2003","unstructured":"Inoue K, Okugawa K, Kato S, Inoue Y, Tomita G, Oshika T, et al. Ocular factors relevant to anti-glaucomatous eyedrop-related keratoepitheliopathy. J Glaucoma. 2003;12:480\u20135.","journal-title":"J Glaucoma"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00856-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10384-021-00856-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-021-00856-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,23]],"date-time":"2021-08-23T04:07:49Z","timestamp":1629691669000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10384-021-00856-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,19]]},"references-count":36,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1007\/s10384-021-00856-2","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,19]]},"assertion":[{"value":"28 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y. Saito, Grant (Otsuka); J. Kizaki, Grant (Otsuka); Y. Wada, Grant (Otsuka); Y. Shibasaki, Employee (Otsuka); N. Kishimoto, Employee (Otsuka); M. Aihara, Grant (Otsuka).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}